Condition
COVID 19 Vaccine
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Unknown4
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05057182Phase 4UnknownPrimary
Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)
NCT04659941Phase 2UnknownPrimary
Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers
NCT05729191Completed
Evaluation of the Acceptance of the Anti-COVID-19 Vaccine Offer Among Pregnant Women
NCT05162482Phase 2UnknownPrimary
Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID)
NCT04809948UnknownPrimary
Effects of COVID 19 Vaccine on Egyptian Population
Showing all 5 trials